NHS reimburses Roche's Hemlibra in new group of haemophilia ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug.

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

BioMarin seeks haemophilia gene therapy approval after promi...

BioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified clinical criteria for regulatory review.

The unmet needs of bleeding disorder patients

Ahead of eyeforpharma Philadelphia 2019, we talk to speaker and haemophilia advocate Michelle Rice about the changing landscape for bleeding disorders

EU expands use of Roche's new haemophilia A drug

The European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the use of the drug that is expected to drive sales as blockbus

Gene therapy firm BioMarin stages haemophilia musical

BioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression helps patients, as it develops an experimental cure for th